The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast CancerMarch 3rd 2020
What We're Reading: Gilead Dealt Patent Setback; Merck Spins Off Businesses; Governors' Medicaid WorriesFebruary 6th 2020
The Patent Trial and Appeals Board delivered a setback to Gilead Sciences, rejecting its attempt to invalidate a pair of Truvada patents owned by the CDC; Merck is spinning off some businesses in order to focus on its oncology drug pembrolizumab, including its biosimilars operations; Republican and Democratic governors are worried that a proposed CMS fiscal accountability rule for Medicaid will reduce access to healthcare.
PAPER OF THE WEEK: In 2002, Researchers Found Early Use of Etanercept Improved Quality of Life In RAJanuary 17th 2020
As part of our anniversary celebration, today we launch “Paper of the Week,” which will look back at some of the most influential research articles and commentary that have appeared in The American Journal of Managed Care® over the past 25 years, and why they are important today.
Phase 3 Trial Enrollment Approved in China for Samsung Bioepsis' Biosimilar EculizumabJanuary 11th 2020
The biosimilar candidate treats paroxysmal nocturnal hemoglobinuria, a rare blood condition that features destruction of red blood cells, thrombosis, and impaired bone marrow function.
Empower Physicians to Fight Financial Toxicity With BiosimilarsDecember 16th 2019
The availability of biosimilars introduces competition based on price, offering a lower-cost alternative in the short term and helping to restrict—or even reverse—longer-term price growth.
Dr Elaine Husni: Huge Savings With Biosimilars Have Not ManifestedNovember 12th 2019
While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.
2019 Brought Impressive Results for TNF Inhibitors, Research Into Monotherapy, Interest in CBDNovember 10th 2019
This year has been an exciting time for rheumatologists with impressive clinical trial results and promising outcomes for patients, said Susan Manzi, MD, MPH, codirector of the Lupus Center of Excellence and chair of the Department of Medicine of West Penn Allegheny Health System, during a session at the American College of Rheumatology annual meeting in Atlanta, Georgia.
What We're Reading: Democrats Win With Medicaid Work Rule Promise; Trump Says No to Pelosi Plan; UnitedHealthcare Biosimilar SwitchingNovember 6th 2019
Medicaid work requirements were front and center in the outcomes of Kentucky governor's race as well as the statehouse in Virginia; the Trump administration called the drug plan from House Speaker Nancy Pelosi, D-California, "unworkable;" UnitedHealthcare is switching patients to biosimilar epoetin alfa in 2020;
Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial ToxicityNovember 5th 2019
We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Preparing for the Near-Term Pipeline of Therapies, and Opportunities for Cost SavingsOctober 31st 2019
Increased competition is making its way into the specialty drug market, affecting orphan conditions, cancer types, and even common specialty conditions, which is presenting some cost savings opportunities, explained Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts, who presented on the specialty pharmaceutical pipeline during her regular session at AMCP Nexus 2019.
Providers Move Forward With 2-Sided Risk and Take on PharmaOctober 29th 2019
Heading into 2019, the idea that oncology practices would fully embrace financial responsibility for clinical decisions still seemed far-fetched for many. And yet, when it was time to make the call, moving to 2-sided risk proved a “simple” decision, said Travis Brewer of Texas Oncology, who took part in a panel offering an update on the Oncology Care Model (OCM) at the start of the Community Oncology Alliance (COA) Payer Exchange Summit, which opened Monday in Tyson’s Corner, Virginia.
How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?September 27th 2019
From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.
This Week in Managed Care: August 9, 2019August 9th 2019
This week, the top managed care stories included CMS giving chimeric antigen receptor T-cell payments a boost; a US task force announcing that those at risk for pancreatic cancer should be screened; FDA revealing Novartis withheld data about a high-cost gene therapy.
What We're Reading: Measles Quarantines; Roche's Cancer Drug Competition; Blood Pressure Targets for T2DApril 29th 2019
Nearly 700 people at California State University and the University of California, both in Los Angeles, were still in quarantine over the weekend after possibly being exposed to measles; the world’s largest seller of cancer drugs, pharma company Roche Holding AG, will lose its top spot with competition from lower-cost drugs, namely biosimilars; findings from a new study showed that blood pressure regulation at or below 130/80 mm Hg lowered the risk of heart attack, stroke, or other complications in patients with type 2 diabetes (T2D).